Heart Failure — Page-by-Page Explanation (Harrison's Principles of Internal Medicine, 22nd Ed., Ch. 257–258) 1. Title slide — Introduces the topic. Heart failure (HF) is one of the most common final pathways for cardiovascular disease and remains a leading cause of hospitalization worldwide. 2. Definition (chronic CV diseases → HF) — This slide frames HF as the end result of long-standing cardiovascular insults rather than a disease in itself. Hypertension causes chronic pressure overload, coronary artery disease causes myocardial ischemia/infarction with loss of contractile tissue, and valvular disease causes pressure or volume overload — all three converge on the common syndrome of heart failure. 3. Definition (ACCF/AHA and HFA) — Harrison's emphasizes that HF is not a single disease but a clinical syndrome: a constellation of symptoms and signs (dyspnea, fatigue, fluid retention) arising from any structural or functional problem that impairs the ventricle's ability to fill with blood (diastolic problem) or eject it (systolic problem). This definition is deliberately broad because many different underlying etiologies can produce the same clinical picture. 4. Definition (Chronic/Acute HF/Acute pulmonary edema) — This distinguishes HF by tempo. Chronic HF is the baseline state most patients live with for months to years. Acute HF (previously "acute decompensated HF") is a sudden worsening — most often a chronic HF patient tipping over the edge (from missed medications, dietary indiscretion, infection, arrhythmia), with only about 1 in 5 cases being truly brand-new HF (e.g., from a big heart attack). Acute pulmonary edema is the most dramatic and dangerous presentation — a sudden, severe backup of pressure into the lungs. 5. Prevalence graph (NHANES 2013–2016) — Demonstrates that HF prevalence rises steeply with age (from <0.5% in young adults to ~12–13% in those ≥80), and that men have somewhat higher prevalence than women, especially in older age brackets. This underlines why HF is fundamentally a disease of aging populations. 6. Mortality and Morbidity — HF carries a prognosis comparable to many cancers: roughly half of patients diagnosed with HF die within 5 years, and in severe/advanced HF, mortality can reach 40% within just one year. This is why early recognition and guideline-directed therapy matter so much. 7. Table 257-1: Predictors of Adverse Outcomes — Groups risk factors into clinical (age, sex, comorbidities, symptoms), structural (poor EF, dilated ventricles), hemodynamic (high filling pressures, low cardiac output), biochemical (renal dysfunction, low sodium, elevated biomarkers), and electrophysiologic (arrhythmias) categories — a reminder that prognosis in HF is multi-dimensional, not just "how low is the EF." 8. Table 257-2: Selected Causes of HF — Organizes etiology by the type of HF produced. HFrEF classically results from things that kill or weaken myocardium (ischemia, infection, toxins, infiltration). HFpEF classically results from things that make the ventricle stiff (hypertension, restrictive/infiltrative disease, aging) while contractile function is preserved. High-output HF is a distinct, less common category where the heart fails not because it's weak, but because peripheral demand for blood flow exceeds even a normal heart's capacity (thyrotoxicosis, severe anemia, AV shunts). 9–10. Stages of HF (A–D) — This is the ACC/AHA staging system, which is fundamentally different from the NYHA functional class (below) because it is progressive and irreversible — patients move forward through stages but never back. Stage A = risk factors only, no heart disease yet. Stage B = structural heart disease present but asymptomatic (this is where "pre-heart failure" biomarker/imaging findings matter). Stage C = structural disease plus current or prior symptoms. Stage D = end-stage, refractory to standard therapy. This staging exists to prompt earlier intervention — treatment should begin at Stage A/B, not wait until symptoms appear. 11. Table 4: Classification of HF by LVEF — This is the newer, unified nomenclature (2021+) replacing the older simple "systolic vs diastolic HF" split. HFrEF (EF ≤40%) is the classic "weak pump" phenotype with the strongest evidence base for drug therapy. HFmrEF (41–49%) is a newer intermediate category that shares some treatment responsiveness with HFrEF. HFpEF (≥50%) reflects a stiff, non-compliant ventricle. HFimpEF is a clinically important new category — patients whose EF has recovered above 40% with treatment — because these patients still need lifelong GDMT, as the improvement is often treatment-dependent, not a cure. 12. Pathophysiology intro — Sets up the concept that HF is a progressive disease driven by an initiating "index event" (an MI, valve lesion, genetic cardiomyopathy) that sets off structural remodeling over months to years — the heart doesn't fail overnight; it deteriorates through a self-perpetuating pathologic process. 13. Progressive disease slide — Key teaching point from Harrison's: patients are often asymptomatic for a long time after the initial insult because compensatory mechanisms (sympathetic activation, RAAS activation, hypertrophy) temporarily maintain cardiac output — but paradoxically, these same compensations are what drive the disease forward, so by the time symptoms appear, significant remodeling has already occurred. 14. Remodeling stimuli diagram — Shows how mechanical wall stress, cytokines, neurohormones, and oxidative stress all converge to produce myocyte hypertrophy, altered extracellular matrix, reactivation of fetal genes, disturbed calcium handling, and myocyte death — collectively causing ventricular enlargement and systolic/diastolic dysfunction, which in turn increases wall stress again — a vicious cycle. 15. Neurohumoral activation diagram (Fig 16.23) — Illustrates the central vicious circle of HF: reduced cardiac output triggers sympathetic nervous system, RAAS, vasopressin, and endothelin activation as compensatory mechanisms to maintain blood pressure and organ perfusion. But these systems cause vasoconstriction (increased afterload) and sodium/water retention (increased preload/volume) — both of which increase cardiac work and further damage myocytes, worsening HF. This is the physiologic rationale for why HF drugs (ACEi/ARB, beta-blockers, MRAs) work — they block this maladaptive cycle. 16–17. Ventricular remodeling / concentric vs eccentric hypertrophy — Explains Laplace's law in action: pressure overload (hypertension, aortic stenosis) causes the ventricle to add wall thickness relative to chamber size to normalize wall stress = concentric hypertrophy (thick walls, small cavity). Volume overload (aortic/mitral regurgitation) causes the chamber to dilate more than the wall thickens = eccentric hypertrophy (large cavity). This distinction matters clinically because it predicts the mechanical problem (diastolic stiffness vs systolic dilation) and helps explain imaging findings. 18. Novel Biologic Targets — SGLT2 — SGLT2 is normally a glucose transporter in the kidney; in HF, its excess activity contributes to fluid retention and abnormal myocardial metabolism/calcium handling — independent of diabetes status. This explains why SGLT2 inhibitors (originally diabetes drugs) reduce HF hospitalization and mortality even in non-diabetic HF patients, and are now a pillar of GDMT. 19–29. History section — Walks through the symptom complex of HF, explained by two parallel mechanisms: (1) backward failure/congestion — fluid backs up behind the failing ventricle, causing pulmonary congestion in left HF (dyspnea, orthopnea, PND) or systemic congestion in right HF (edema, hepatomegaly, ascites, GI symptoms); and (2) forward failure/low output — insufficient cardiac output to perfuse tissues, causing fatigue, exertional intolerance, cognitive symptoms in the elderly, and eventually oliguria in advanced disease. Orthopnea and PND specifically reflect fluid redistribution from the periphery into the central circulation when lying flat, worsening pulmonary congestion. The NYHA Functional Classification (Table 257-4) is a symptom-based, dynamic severity scale (unlike ACC/AHA staging) — patients can move up or down NYHA class with treatment, which is why it's used to track response to therapy. 30–34. Physical Examination — General appearance in severe HF reflects both congestion (dyspnea, diaphoresis) and low output (pallor/duskiness, cool extremities). Cardiac cachexia is a marker of very advanced, chronic disease driven by anorexia, malabsorption from bowel edema, and catabolic cytokine activation. Vital signs show compensatory tachycardia and, in decompensated states, narrow pulse pressure/hypotension reflecting critically low stroke volume; pulsus alternans reflects beat-to-beat variation in contractility. Elevated JVP, hepatojugular reflux, Kussmaul's sign, rales, S3/S4 gallops, and hepatomegaly are the classic bedside signs of volume overload and are incorporated into diagnostic scoring systems like the Modified Framingham Criteria (major and minor criteria) — a reminder that HF, especially historically, is a clinical diagnosis supported by, not solely dependent on, imaging/labs. 35–40. Diagnostic workup — Follows the standard funnel: history/exam → routine labs (renal function is critical because it's both a marker of severity and affects drug dosing; thyroid and metabolic screening rule out reversible causes) → chest X-ray (cardiomegaly, congestion, effusions) → ECG (nonspecific, but helps point toward etiology — LVH/LAE suggests HFpEF causes, Q waves suggest prior infarction) → echocardiography, the single most useful test because it directly measures EF and structural abnormalities and determines HF phenotype (HFrEF/HFmrEF/HFpEF) → CMR for tissue characterization when infiltrative disease is suspected → natriuretic peptides (BNP/NT-proBNP) as an adjunct, especially useful for ruling HF in/out when the clinical picture is ambiguous, keeping in mind many non-cardiac conditions (renal failure, sepsis, age, AF) can also raise levels → invasive studies (coronary angiography to exclude ischemic etiology, biopsy in select cases) reserved for specific indications. 41–43. Diagnostic algorithm summary — Consolidates the above into a stepwise flow: assess clinically → check natriuretic peptides if uncertain → echo to confirm and classify by EF → determine cause and initiate treatment. 44. ESC Classes of Recommendation — A guideline literacy slide: Class I = should do it (strong evidence), Class IIa = reasonable to do, Class IIb = may consider (weaker evidence), Class III = don't do it (harmful or no benefit). This coding is used throughout the following management algorithms (the numbers in parentheses on later slides refer to these classes). 45–48. Stages A–D again, now with management overlaid — Shows that management should start at Stage A (risk-factor control: BP control, SGLT2i in diabetics with CVD risk, treating known CVD, avoiding cardiotoxins, genetic counseling in familial cardiomyopathy) and intensify at Stage B once structural disease is found (ACEi for low EF, beta-blockers, ICD if very low EF, genetic testing). 49. Stage C algorithm (HFrEF) — This is the core evidence-based drug algorithm for HFrEF, the "four pillars" of GDMT: ARNi (preferred) or ACEi/ARB, beta-blocker, MRA, and SGLT2i — all initiated together and up-titrated, plus diuretics as needed for congestion. Additional therapies (hydralazine-nitrates especially in Black patients with advanced symptoms, ICD for primary prevention of sudden death, CRT-D for those with wide QRS/LBBB) are layered on for specific scenarios. Refractory disease (Stage D) triggers referral for mechanical circulatory support, transplant, or palliative care. 50. HFmrEF treatment — Reflects weaker evidence: diuretics are Class I for congestion, SGLT2i is Class IIa, while ACEi/ARB/ARNi, MRA, and evidence-based beta-blockers are only Class IIb — meaning they "may be considered" rather than are strongly recommended, since the trial evidence in this EF range is less robust than in HFrEF. 51. HFpEF treatment — Similarly, diuretics for symptom relief are Class I, SGLT2i is Class IIa (the strongest pharmacologic evidence in HFpEF to date), while ARNi, MRA, and ARB are Class IIb — reflecting that HFpEF has historically been much harder to treat pharmacologically because the underlying problem (stiffness, not weak contraction) doesn't respond as well to neurohormonal blockade. 52. Neurohormonal cycle with drug targets — Ties the pathophysiology back to pharmacology: shows exactly where each drug class intervenes — ACEi/ARB/ARNi/beta-blockers/MRA block the SNS-RAAS-vasopressin axis; diuretics interrupt the renal perfusion/sodium retention arm; vasodilators reduce afterload; cardiac glycosides (digoxin) act to boost contractility/reduce heart rate. This slide is essentially the "why" behind every drug on the next table. 53. Table 258-2: GDMT drugs and target doses — A practical reference for actual starting and target doses of ACEi, ARBs, MRAs, beta-blockers, hydralazine/nitrates, and ARNi (sacubitril-valsartan) used in HFrEF, plus emerging agents (vericiguat, SGLT2 inhibitors, omecamtiv mecarbil) under investigation at the time of writing. The key clinical teaching point Harrison's emphasizes is that these drugs should be up-titrated to the target dose (not just the starting dose) as tolerated, since outcome benefits are dose-related. Explain everything like a middle class student can understand and don't miss any content

Create a study guide summarizing heart failure stages and treatment